<DOC>
	<DOC>NCT01474421</DOC>
	<brief_summary>This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.</brief_summary>
	<brief_title>Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patients with Parkinson's disease Patients with dyskinesias for at least 3 months Patients with moderate to severe dyskinesias Patients on Ldopa treatment for at least 3 years Patients with atypical Parkinson's disease Patients who have had prior surgery for Parkinson's disease Patients who are cognitively impaired, have psychosis, have confusional states or hallucinate Patients who received neuroleptics or antipsychotics within 2 months Women of childbearing potential Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Parkinson's disease</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Movement disorders</keyword>
	<keyword>L-dopa</keyword>
</DOC>